May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Night–Vision Symptoms as a Risk Factor for Vision Loss and Choroidal Neovascularization in the Complications of Age–related Macular Degeneration Prevention Trial (CAPT)
Author Affiliations & Notes
  • G.–S. Ying
    Ophthalmology, Scheie Eye Inst, Univ of Pa, Philadelphia, PA
  • C. Liu
    Ophthalmology, Scheie Eye Inst, Univ of Pa, Philadelphia, PA
  • M.G. Maguire
    Ophthalmology, Scheie Eye Inst, Univ of Pa, Philadelphia, PA
  • CAPT Research Group
    Ophthalmology, Scheie Eye Inst, Univ of Pa, Philadelphia, PA
  • Footnotes
    Commercial Relationships  G. Ying, None; C. Liu, None; M.G. Maguire, None.
  • Footnotes
    Support  SupNIH grant EY 12279, RC EY12211.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 204. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G.–S. Ying, C. Liu, M.G. Maguire, CAPT Research Group; Night–Vision Symptoms as a Risk Factor for Vision Loss and Choroidal Neovascularization in the Complications of Age–related Macular Degeneration Prevention Trial (CAPT) . Invest. Ophthalmol. Vis. Sci. 2005;46(13):204.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Abstract:
 

 

To describe night–vision symptoms at baseline and assess their association with subsequent 3–lines loss in visual acuity (VA) and choroidal neovascularization (CNV) in untreated eyes of CAPT participants.

 

 

1052 CAPT participants with ≥ 10 large drusen (>125µ) and visual acuity ≥ 20/40 in each eye participated. At baseline, each participant self–administered a 10–item questionnaire on night–vision symptoms (NVRQ–10) that was scaled to score participants with no symptoms as 100. Visual acuity testing (ETDRS Charts 1, 2) was performed by certified examiners at baseline, 6 months and annually. CNV was identified by trained readers using fluorescein angiography. Evaluation of baseline NVRQ–10 score as a risk factor for 3–lines loss in VA and CNV was performed by repeated–measures logistic regression and survival analysis, with and without the adjustment of participant characteristics (age and smoking status) and ocular characteristics (baseline area covered by drusen and focal hyperpigmentation).

 

 

At baseline, the mean (±SD) NVRQ–10 was 70 (±20), and the median was 73.0 (range: 3 –100). Median follow–up was 48 months. For untreated eyes, participants with lower (≤ median) NVRQ–10 scores were associated with increased risk of 3–lines loss in VA; odds ratio (OR) is 1.69 (95% C.I.: 1.24 – 2.31) compared to participants with higher scores (p=0.001). There was no statistically significant association between lower NVRQ–10 scores and CNV incidence; relative risk (RR) is 1.30 (95% C.I.: 0.85 – 1.99). These relationships were maintained after adjustment of participant and ocular characteristics (Table).

 

Table: Association of lower NVRQ–10 score with 3–lines loss in VA and CNV in untreated eyes

 

 

 

CAPT participants who reported more night vision symptoms at baseline had an increased risk of 3–lines loss in VA but no apparent increased risk of CNV in their untreated eye. The association with VA loss is independent of established risk factors.

 

 
Keywords: age-related macular degeneration • visual acuity • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×